Хайлтын үр дүнгүүд - Carla Boquimpani

Үр дүнг сайжруулах
  1. 1
    Resource Use and Costs Associated with the Treatment of Adverse Events in Chronic Myeloid Leukemia (CML) Brazilian Patients

    Resource Use and Costs Associated with the Treatment of Adverse Events in Chronic Myeloid Leukemia (CML) Brazilian Patients -н Marcelo Ribeiro‐Alves, Carla Boquimpani

    Хэвлэсэн 2014
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS): an urgent need for treatment management

    Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS): an urgent need for treatment management -н Carla Boquimpani, André Abdo, Denise Pires Martins, Luciana Britto de Abreu Lima, Mayde Seadi Torriani, Israel Bendit

    Хэвлэсэн 2020
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors

    Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors -н Ehab Atallah, Michael J. Mauro, Andreas Hochhaus, Carla Boquimpani, Yosuke Minami, Vikalp Kumar Maheshwari, Lovneet Saini, Regina Corbin, Delphine Réa

    Хэвлэсэн 2023
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Impact of Treatment Free Remission (TFR) with Nilotinib in 2nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment

    Impact of Treatment Free Remission (TFR) with Nilotinib in 2nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare Syste... -н André Abdo, Carla Boquimpani, Douglas Vivona, Viviane Silveira Leite, Alisson L. Matsuo, Vanessa Teich, Israel Bendit, Eduardo Magalhães Rego, Vanderson Rocha

    Хэвлэсэн 2018
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors

    ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors -н Massimo Breccia, Anna Turkina, Carla Boquimpani, Charles Chuah, Giora Sharf, Luigi Di Caprio, Matthias Hoch, Justin Yssel, Yifan Zhang, Andreas Hochhaus

    Хэвлэсэн 2022
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice

    Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice -н Carla Boquimpani, Fernanda Salles Seguro, Gustavo Henrique Romani Magalhães, Ingrid Luise Soares Pinto, Israel Bendit, Jaisson Bortolini, Kátia Bórgia Barbosa Pagnano, Renato Centrone, Vaneuza Araújo Moreira Funke

    Хэвлэсэн 2022
    Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  7. 7
    Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial

    Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial -н Delphine Réa, Carla Boquimpani, Michael J. Mauro, Yosuke Minami, Alex Allepuz, Vikalp Kumar Maheshwari, Denise D’Alessio, Ying Wu, Rachael Lawrance, Šarūnas Narbutas, Giora Sharf, Andreas Hochhaus

    Хэвлэсэн 2023
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  8. 8
    CML-398 Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

    CML-398 Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) i... -н Michael J. Mauro, Andreas Hochhaus, Timothy P. Hughes, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jane F. Apperley, Valentín García‐Gutiérrez, S. S. Kapoor, Noemi Espurz, Vishal Dhamal, Jorge E. Cortés

    Хэвлэсэн 2023
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  9. 9
    P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY

    P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHAS... -н Timothy P. Hughes, Delphine Réa, Carla Boquimpani, Yosuke Minami, Michael J. Mauro, Jorge E. Cortés, Jane F. Apperley, Valentín García‐Gutiérrez, S. S. Kapoor, Meryem Ktiouet-Dawson, Vishal Dhamal, Andreas Hochhaus

    Хэвлэсэн 2023
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  10. 10
    Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

    Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3... -н Timothy P. Hughes, Delphine Réa, Carla Boquimpani, Yosuke Minami, Michael J. Mauro, Jorge E. Cortés, Jane F. Apperley, Valentín García‐Gutiérrez, S. S. Kapoor, Alex Allepuz, Sarah Quenet, Yifan Zhang, Andreas Hochhaus

    Хэвлэсэн 2022
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  11. 11
    P668: CHRONIC MYELOID LEUKEMIA SURVEY ON UNMET NEEDS (CML SUN): BALANCING TOLERABILITY AND EFFICACY GOALS OF PATIENTS AND PHYSICIANS THROUGH SHARED TREATMENT DECISION-MAKING

    P668: CHRONIC MYELOID LEUKEMIA SURVEY ON UNMET NEEDS (CML SUN): BALANCING TOLERABILITY AND EFFICACY GOALS OF PATIENTS AND PHYSICIANS THROUGH SHARED TREATMENT DECISION-MAKING -н Fabian Lang, Zack Pemberton‐Whiteley, Joannie Clements, Cristina Ruiz, Delphine Réa, Lisa Machado, Naoto Takahashi, Sungho Moon, Andrew Grigg, Cornelia Borowczak, Peter Schuld, Pauline Frank, Cristina Constantinescu, Carla Boquimpani, Jorge E. Cortés

    Хэвлэсэн 2023
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  12. 12
    <i>Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey</i>

    <i>Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey</i> -н Zack Pemberton‐Whiteley, Jorge E. Cortés, Joannie Clements, Cristina Ruiz, Delphine Réa, Lisa Machado, Fabian Lang, Naoto Takahashi, Nigel Deekes, Sungho Moon, Andrew Grigg, M Mortensen Steagall, Cornelia Borowczak, Virginia Pilipovic, Pauline Frank, Cristina Constantinescu, Carla Boquimpani

    Хэвлэсэн 2021
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  13. 13
    A MULTICENTER NON-INFERIORITY STUDY OF EFFICACY AND SAFETY OF GENERIC IMATINIB IN CHRONIC MYELOID LEUKEMIA – FINAL ANALYSIS

    A MULTICENTER NON-INFERIORITY STUDY OF EFFICACY AND SAFETY OF GENERIC IMATINIB IN CHRONIC MYELOID LEUKEMIA – FINAL ANALYSIS -н KBB Pagnano, Ecm Miranda, Israel Bendit, Fernanda Salles Seguro, Marília Ferrari Conchon, NN Gonçalves, GH Magalhães, Nelma Clementino, Davimar Miranda Maciel Borducchi, Ni WAS Andari, André Coelho, Ingrid Luise, Laura Fogliatto, Jaisson Bortolini, Renato Centrone, Carla Boquimpani, Cármino Antônio De Souza

    Хэвлэсэн 2021
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  14. 14
    COVID-19 IN CHRONIC MYELOID LEUKEMIA PATIENTS – BRAZILIAN EXPERIENCE

    COVID-19 IN CHRONIC MYELOID LEUKEMIA PATIENTS – BRAZILIAN EXPERIENCE -н KBB Pagnano, AC Toreli, AT Quixadá, Leila Perobelli, VAM Funke, FS Seguro, Israel Bendit, LVDN Fechio, Jaqueline Sapelli, Jaisson Bortolini, MS Moura, AG Lourenço, NN Gonçalves, Mônika Conchon, Fabio Moore Nucci, LC Palma, POM Hokama, LL Almeida, Cármino Antônio De Souza, Carla Boquimpani

    Хэвлэсэн 2021
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  15. 15
    PF411 ENESTOP 192‐WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT‐FREE REMISSION (TFR) FOLLOWING SECOND‐LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML)

    PF411 ENESTOP 192‐WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT‐FREE REMISSION (TFR) FOLLOWING SECOND‐LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC M... -н François‐Xavier Mahon, Carla Boquimpani, Nahoto Takahashi, Noam Benyamini, Nelma Clementino, Vasily Shuvaev, J. H. Lipton, Anna Turkina, Raquel De Paz Arias, Beatriz Moiraghi, Franck E. Nicolini, Jolanta Dengler, Tomasz Sacha, D.‐W. Kim, Rafik Fellague-Chebra, Sandip Acharya, Catherine Bouard, Timothy P. Hughes

    Хэвлэсэн 2019
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  16. 16
    Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry

    Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry -н Irène Biasoli, Nelson Castro, Carolina Colaço Villarim, Fabı́ola Traina, Carlos Chiattone, Monica Praxedes, Cristiana Solza, Leila Perobelli, Otávio Baiocchi, Rafael Dezen Gaiolla, Carla Boquimpani, Valéria Buccheri, Caroline Sola, R. Silva, Ana Carolina Ribas, Giovanna Steffenello, Kátia Bórgia Barbosa Pagnano, Andréa Soares, Cármino Antônio De Souza, Nelson Spector

    Хэвлэсэн 2023
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  17. 17
    Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel

    Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel -н Carolina Pavlovsky, Virginia Abello Polo, Kátia Bórgia Barbosa Pagnano, Ana Inés Varela, Claudia Agudelo, Michele Bianchini, Carla Boquimpani, Renato Centrone, Mônika Conchon, Nancy Delgado, Vaneuza Araújo Moreira Funke, Isabel Giere, Ingrid Luise, Luis Meillón, Beatriz Moiraghi, Juan Ramón Navarro, Lilian Pilleux, Ana Inés Prado, Soledad Undurraga, Jorge E. Cortés

    Хэвлэсэн 2021
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  18. 18
    Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

    Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis -н Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson, Dong‐Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Étienne, Carla Boquimpani, Ricardo Pasqüini, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Sławomira Kyrcz‐Krzemień, Ewa Mędraś, Maria Aparecida Zanichelli, Israel Bendit, Silvia Cacciatore, Ksenia Titorenko, Paola Aimone, Giuseppe Saglio, Andreas Hochhaus

    Хэвлэсэн 2021
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  19. 19
    Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

    Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis -н Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson, Dong‐Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Étienne, Carla Boquimpani, Ricardo Pasqüini, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Sławomira Kyrcz‐Krzemień, Ewa Mędraś, Maria Aparecida Zanichelli, Israel Bendit, Silvia Cacciatore, Ksenia Titorenko, Paola Aimone, Giuseppe Saglio, Andreas Hochhaus

    Хэвлэсэн 2021
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  20. 20
    Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

    Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis -н Timothy P. Hughes, Giuseppe Saglio, Richard A. Larson, Hagop M. Kantarjian, Dong-Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Étienne, Carla Boquimpani, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Sławomira Kyrcz‐Krzemień, Ewa Mędraś, Maria Aparecida Zanichelli, Israel Bendit, Manu Sondhi, Ksenia Titorenko, Claire Nourry-Boulot, Paola Aimone, Andreas Hochhaus

    Хэвлэсэн 2019
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: